SCHEMBL80897

SCHEMBL80897

CC(C)N(C(C)C)P(OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
IDO1 P14902 1/20 0.39
KMT2A Q03164 2/20 0.39
AGXT P21549 1/20 0.38
ALDH1A1 P00352 2/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
MAPK1 P28482 2/20 0.37
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
SLC6A2 P23975 3/20 0.36
TAAR1 Q96RJ0 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
MAOA P21397 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
CYP2A6 P11509 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5831072 0.87 CA1 (0.33) TSHRIDO1KMT2AALDH1A1CA1
SCHEMBL12380718 0.87 FFAR1 (0.35) TSHRKMT2AALDH1A1CA1CA2
SCHEMBL2252915 0.85 TSHR (0.41) TSHRIDO1KMT2AAGXTALDH1A1
SCHEMBL2227585 0.83 TSHR (0.40) TSHRIDO1KMT2AAGXTALDH1A1
SCHEMBL6578072 0.83 LTA4H (0.44) TSHRALDH1A1CA1CA2HTT
SCHEMBL4881254 0.83 MAOB (0.34) TSHRKMT2AALDH1A1LMNA
SCHEMBL5831071 0.83 TSHR (0.32) TSHRIDO1KMT2AALDH1A1MAPK1
SCHEMBL24027472 0.82 TSHR (0.36) TSHRIDO1KMT2AAGXTALDH1A1
SCHEMBL2240873 0.81 KMT2A (0.40) TSHRIDO1KMT2AALDH1A1MAPK1
SCHEMBL2261012 0.81 TSHR (0.39) TSHRIDO1KMT2AAGXTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751521-A Synthesis method of antitumor and antiangiogenic medicine PI-88 and precursor thereof 陕西师范大学 2025-04-04 CN claimed
US-12258506-B2 Films comprising bright silver based quaternary nanostructures SHOEI CHEMICAL INC. (JP) 2025-03-25 US claimed
EP-3707147-B1 NEW SYNTHETIC AGONISTS OF TLR4 RECEPTOR UNIV DEGLI STUDI DI MILANO BICOCCA (IT) 2025-03-05 EP claimed
CN-119080856-A Mutant tRNA for codon extension 中外制药株式会社 2024-12-06 CN claimed
US-20240209257-A1 FILMS COMPRISING BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES SHOEI CHEMICAL INC. (JP) 2024-06-27 US claimed
US-11926776-B2 Films comprising bright silver based quaternary nanostructures SHOEI CHEMICAL INC. (JP) 2024-03-12 US claimed
EP-4314193-A1 STABLE AIGS FILMS Shoei Chemical Inc. (JP) 2024-02-07 EP claimed
CN-117396581-A Stable AIGS film 纳米系统公司 2024-01-12 CN claimed
EP-4267691-A1 FILMS COMPRISING BRIGHT SILVER BASED QUATERNARY NANOSTRUCTURES Nanosys, Inc. (US) 2023-11-01 EP claimed
CN-116981754-A Film comprising bright silver-based quaternary nanostructures 纳米系统公司 2023-10-31 CN claimed
EP-2069339-A2 SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES Wockhardt Research Centre (IN) 2009-06-17 EP claimed
WO-2008058156-A9 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC (US) 2008-12-04 WO claimed
WO-2008058156-A2 GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS JINA PHARMACEUTICALS INC. (US) 2008-05-15 WO claimed
WO-2008038092-A2 SUBSTITUTED PIPERIDINOPHENYL OXAZOLIDINONES WOCKHARDT RESEARCH CENTRE (IN) 2008-04-03 WO claimed
WO-2006012425-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2006-02-02 WO claimed
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2005-05-19 US claimed
EP-1521762-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2005-04-13 EP claimed
US-20040267007-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor CORIXA CORPORATION 2004-12-30 US claimed
WO-2004005308-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2004-01-15 WO claimed
US-5756774-A Synthesis of myo-inositol phosphates ELAN PHARMACEUTICALS, INC. 1998-05-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267007-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors and intermediates therefor DDOST, STT3A, STT3B TSHR 4214/4885IDO1 1271/4885KMT2A 3405/4885
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor DDOST, AGL, GALE TSHR 3883/4885IDO1 1459/4885KMT2A 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.